Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
san francisco blog main
8
×
clinical trials
boston blog main
boston top stories
new york blog main
new york top stories
san francisco top stories
deals
fda
national top stories
cancer drugs
glaxosmithkline
medical device
national
raleigh-durham blog main
raleigh-durham top stories
satsuma pharmaceuticals
springworks therapeutics
startups
10x genomics
abbvie
acute myeloid leukemia
allergan
amgen
avexis
biotech ipos
boston
boulder/denver blog main
boulder/denver top stories
brian kaspar
cancer immunotherapy
centers for disease control and prevention
detroit blog main
detroit top stories
dihydroergotamine
eli lilly
epigenetics
What
biotech
8
×
companies
ipo
research
days
medicines
new
drug
drugs
hasn’t
ipos
leading
life
news
roundup
satsuma
science
slowed
springworks
street
therapeutics
wall
week
welcomed
abbvie
according
activity
aims
akcea
alliance
approach
arrival
august
based
bio
black
boost
busy
called
cancer
Language
unset
8
×
Current search:
unset
×
biotech
×
" san francisco blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
